Meet Inventiva’s Board of Directors and the expertise guiding our strategy, governance and mission to develop innovative therapies for MASH.
Dr. Mark Pruzanski is a physician and entrepreneur with more than 30 years of experience in the life sciences. Most recently he served as Chairman and Chief Executive Officer of Versanis Bio where he spearheaded the development of novel therapies for obesity and other cardiometabolic diseases until the company’s acquisition in 2023 by Eli Lilly […]
Renée Aguiar-Lucander is CEO of Hansa Biopharma as of April 2025. She was previously CEO of Calliditas Therapeutics, where she led the transformation of the company from a small biotech into a NASDAQ-listed, commercial-stage leader in rare diseases, culminating in its $1.1 billion acquisition by Asahi Kasei in 2024. Under her leadership, Calliditas achieved the […]
Dr. Srinivas Akkaraju is the Founder and Managing General Partner of Samsara BioCapital. Before establishing Samsara, he served as a General Partner at Sofinnova Ventures from 2013 to 2016, and as Managing Director at New Leaf Venture Partners from 2009 to 2013. Dr. Akkaraju also held the position of Managing Director at Panorama Capital, LLC, […]
Dr. Barbara Krebs-Pohl holds a Ph.D. with a focus on antibody technologies and brings over 27 years of experience in biotechnology development, business strategy, and alliance creation. She most recently served as Chief Business Officer at MorphoSys, where she led the company’s acquisition by Novartis for USD 2.9 billion and played pivotal roles in the […]
Heinz Maeusli has been a member of our Board of Directors since 2019. Before joining our Board of Directors, Mr. Maeusli was Chief Financial Officer of Advanced Accelerator Applications (AAA) from 2003 to 2018, where he was instrumental in making this company a leader in the sector of nuclear medicine. In this capacity, he led […]
Dr. Anne Prener holds an M.D. and a Ph.D. in epidemiology from the University of Copenhagen and brings more than 25 years of experience leading clinical-stage biotechnology companies through critical development and value-creation milestones. She has served as Chief Executive Officer of multiple companies, including Freeline Therapeutics, a liver-directed gene therapy company she scaled from […]
Ms. Camilla Soenderby brings 25 years of international leadership experience from executive roles at leading biopharma organizations across the EU, US, and Asia. She formerly served as a corporate officer at Takeda, where she led global portfolio commercialisation and commercial excellence, overseeing global brands with annual revenue of USD 13 billion. Prior to that, she […]
André Turenne has more than 20 years of global experience in the pharmaceutical industry. He is currently President and Chief Executive Officer of the Boston-based biotech Matchpoint Therapeutics, and Advisor to Atlas Venture since 2021. Prior to joining Matchpoint, André Turenne served as President and Chief Executive Officer of Voyager Therapeutics. He previously held senior […]
